Nuvectis Pharma, Inc. (NVCT): Total Assets
$31.71M
As of 2025-12-31
$22.38M
As of 2026-06-30
+15.8%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $31.71M | +70.4% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $18.61M | -3.0% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $19.18M | -6.0% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $20.41M | +206.5% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $6.66M | n/a | 2023-03-08, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | 2025-12-31 | $31.71M | +70.4% |
| Valion Bio, Inc. (VBIO) | 2025-12-31 | $31.61M | n/m |
| Equillium, Inc. (EQ) | 2025-12-31 | $31.89M | +24.5% |
| Tvardi Therapeutics, Inc. (TVRD) | 2025-12-31 | $32.07M | -8.9% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $31.00M | +108.2% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $32.47M | +46.9% |
| PDS Biotechnology Corp (PDSB) | 2025-12-31 | $30.49M | -32.8% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $30.16M | -54.9% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $30.08M | -1.6% |
Compare NVCT, VBIO, EQ, TVRD side by side · Screen every company in Pharmaceutical Preparations ↗